Episurf Medical AB (publ)

Episurf Medical AB (publ) is a Swedish medical technology company that specializes in the development and production of orthopedic implants and surgical instruments. Its innovative solutions are distributed across the Nordic countries, Germany, the United Kingdom, and various international markets. The company offers a range of Episealer implants designed to address localized cartilage and underlying bone defects. These include the Episealer Condyle Solo, specifically for the femoral condyles of the knee joint; the Episealer Trochlea Solo, targeting defects located behind the patella; and the Episealer Femoral Twin, which is used for more extensive, elongated defects found on the femoral condyles and within the trochlea area of the knee. For the ankle, Episurf provides the Episealer Talus, intended for osteochondral lesions of the talar dome. Beyond implants, their product line features surgical drill guides such as Epiguide, and the Epiguide MOS, specifically engineered for mosaicplasty procedures to treat deep cartilage and bone defects in the knee. Episurf also provides µiFidelity, a proprietary order management system. This platform facilitates order placement and tracking, allows for MRI scan uploads, and enables consultation of patient damage marking reports. Established in 2008 and headquartered in Stockholm, Sweden, the company adopted its current name, Episurf Medical AB (publ), in 2010, having previously operated as Diamorph Medtech AB.

Episurf Medical AB (publ) trades as EPIS-B.ST on STO. The company is classified in Healthcare / Medical - Devices and reports in SEK.

The current profile places the business in Medical - Devices. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Detailed operating-segment data is not available for this symbol yet.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Episurf Medical AB (publ) can be compared against peers such as 2cureX AB (publ), Aino Health AB (publ), Chordate Medical Holding AB (publ), ExpreS2ion Biotech Holding AB (publ), Guard Therapeutics International AB (publ), Modus Therapeutics Holding AB (publ).

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $78.57M, beta of 0.58, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

EPIS-B.ST currently shows total debt of N/A and beta of 0.58. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://episurf.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.